comparemela.com

Latest Breaking News On - Aprea therapeutics inc - Page 4 : comparemela.com

Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?

Monday, Aprea Therapeutics Inc APRE announced that the FDA has cleared its Investigational New Drug (IND) application for APR-1051. “APR-1051 is a…

Oren giladAprea therapeutics incInvestigational new drugReaking news

Aprea Therapeutics (APRE) Announces FDA Clearance of IND for APR-1051

Aprea Therapeutics (APRE) Announces FDA Clearance of IND for APR-1051
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Oren giladAprea therapeutics incDrug administrationAprea therapeuticsInvestigational new drug

Aprea Therapeutics (APRE) Announces Private Placement Financing of up to $34 0 Million

Aprea Therapeutics (APRE) Announces Private Placement Financing of up to $34 0 Million
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesOren giladMaxim groupAprea therapeutics incExchange commissionAprea therapeuticsSphera healthcareNantahala capitalExome asset managementStonepine capital managementSynthetic lethalitySecurities act

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

06.02.2024 - DOYLESTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it . Seite 1

Us food drug administrationAprea therapeutics incInvestigational new drugDrug administration

Aprea Therapeutics Announces Submission of IND Application

DOYLESTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage.

United statesMike moyerOren giladSecurities exchangeExchange commissionAprea therapeutics incUs food drug administrationInvestigational new drugDrug administrationSecurities actSecurities exchange actFinancial conditionNasdaq apreAprea therapeutics

vimarsana © 2020. All Rights Reserved.